Aberdeen Group
RCUS icon

Aberdeen Group’s Arcus Biosciences RCUS Stock Holding History

Aberdeen Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6M Buy
769,787
+385,186
+100% +$8.32M 0.03% 473
2025
Q4 		$9.17M Buy
384,601
+52,930
+16% +$1.08M 0.01% 623
2025
Q3 		$4.42M Buy
+331,671
New +$3.45M 0.01% 715

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Aberdeen Group's RCUS Position: Q1 2026 in Review

Aberdeen Group increased its Arcus Biosciences (RCUS) stake by 100% in Q1 2026, buying an estimated $8.32M and bringing the position to 769,787 shares worth $16.6M. The position accounts for 0.03% of the portfolio, ranked #473.

Aberdeen Group first reported a position in RCUS in Q3 2025 and has held it in 3 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Aberdeen Group held 769,787 shares of Arcus Biosciences worth $16.6M as of Q1 2026.
  • Aberdeen Group bought 385,186 Arcus Biosciences shares in Q1 2026, an estimated $8.32M.
  • Arcus Biosciences made up 0.03% of Aberdeen Group's portfolio in Q1 2026, its #473 holding.
  • Aberdeen Group first reported a position in Arcus Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.